제테마
Financials
Valuation Metrics
제테마's Market Cap is ₩1631B. At end of 2025 it was ₩2282B. Ranked #939 of 2,436 in KR market (top 39%), #450 of 1,649 on KOSDAQ (top 27%), #107 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 46%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 163.13B KRW | KR#939/2,436 Sec#107/234 |
| Revenue | 77.07B KRW | KR#1,553/2,436 Sec#100/234 |
| Net Income | -5.75B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 212.23B KRW | KR#1,243/2,436 Sec#93/234 |
| Net Assets | 71.76B KRW | KR#1,630/2,436 Sec#139/234 |
| Employees | 243 | KR#938/2,436 Sec#81/234 |
| Value | ||
| P/B | 2.27x | KR#2,005/2,436 Sec#152/234 |
| P/S | 2.12x | KR#1,856/2,436 Sec#106/234 |
| EV/EBITDA | 82.81x | KR#1,441/2,436 Sec#100/234 |
| FCF Yield | 3.31% | KR#982/2,436 Sec#61/234 |
| Profitability | ||
| ROE | -8.02% | KR#1,853/2,436 Sec#141/234 |
| ROA | -2.71% | KR#1,750/2,436 Sec#127/234 |
| Op. Margin | 4.28% | KR#1,013/2,436 Sec#79/234 |
| Revenue Growth | 1.08% | KR#1,370/2,436 Sec#127/234 |
| Earnings Growth | -309.87% | KR#1,566/2,436 Sec#101/234 |
| Financial Health | ||
| Debt Ratio | 295.74% | KR#2,125/2,436 Sec#219/234 |
| Total Debt | 115.42B KRW | KR#659/2,436 Sec#39/234 |
| FCF | 5.39B KRW | KR#881/2,436 Sec#60/234 |
| Cash | 5.49B KRW | KR#1,954/2,436 Sec#173/234 |
| Current Ratio | 0.43x | KR#2,286/2,436 Sec#224/234 |
| Net Debt/EBITDA | 33.34x | KR#1,494/2,436 Sec#107/234 |
| Performance | ||
| 1Y Return | -34.41% | KR#1,684/2,436 Sec#148/234 |
| 1M Return | -21.45% | KR#2,235/2,436 Sec#220/234 |
| From 52W High | -61.21% | KR#1,772/2,436 Sec#148/234 |
| 1Y MDD | -61.98% | KR#1,527/2,436 Sec#121/234 |
| Trading | ||
| Volume | 113,601 shares | KR#867/2,436 Sec#85/234 |
| Foreign Own. | 3.03% | KR#996/2,436 Sec#97/234 |
| Per Share | ||
| EPS | -141 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,947 KRW | KR#2,042/2,436 Sec#170/234 |
Company Info
Jetema originated in 2009 as a bio research company focused on chitosan-applied DDS development. Through a 2014 merger and the 2015 completion of a filler-exclusive factory, the company entered the medical aesthetic market, successfully venturing into the toxin market in 2024. Jetema actively researches and develops hyaluronic acid fillers, botulinum toxin-based pharmaceuticals, sutures, and lifting threads. The company is expanding its global presence, securing license-out agreements with Brazil (2020) and China (2022), and pursuing export contracts with Thailand and market entry into the US in 2024. Jetema is headquartered in Wonju City, Gangwon-do.